Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

- PMLiVE

Sanofi expands rare disease pipeline with $2.2bn Inhibrx acquisition

The deal includes a mid-stage candidate for alpha-1 antitrypsin deficiency

- PMLiVE

AstraZeneca’s Imfinzi combination shows promise in phase 3 liver cancer study

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

- PMLiVE

Study finds vaccination against COVID-19 reduces long COVID symptoms

The results could help inform public health strategies and vaccination campaigns

- PMLiVE

Researchers uncover role of inherited genetic variants in rare blood cancer

There are around 4,000 cases of myeloproliferative neoplasms in the UK each year

- PMLiVE

BMS, Exelixis and Ipsen announce positive four-year results for kidney cancer regimen

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

Patient Advocate Engagement: A Customer Story

Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current treatment landscape and lived patient...

Impetus Digital

- PMLiVE

Johnson & Johnson’s bladder cancer drug Balversa granted full FDA approval

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

Novartis shares positive phase 3 results for Lutathera in neuroendocrine tumours

The incidence of neuroendocrine tumours has increased over the past several decades

- PMLiVE

BMS presents promising late-stage results for Opdivo plus Yervoy in colorectal cancer

More than 1.9 million cases of colorectal cancer were diagnosed globally in 2020

- PMLiVE

Precision medicine – revolutionising treatment for genetic diseases and cancer

PME talks to Joanne Kanaan from Omini about the potential role of precision medicine in chronic diseases and the challenges patients face in managing their conditions

- PMLiVE

OPEN Health Appoints Steven Duryee as Chief Operating and Transformation Officer

OPEN Health Appoints Steven Duryee as Chief Operating and Transformation Officer

OPEN Health

- PMLiVE

MHRA approves UCB’s Zilbrysq as generalised myasthenia gravis add-on therapy

The autoimmune disease has a global prevalence of 100 to 350 cases per every one million people

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links